JP2017530130A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530130A5 JP2017530130A5 JP2017516415A JP2017516415A JP2017530130A5 JP 2017530130 A5 JP2017530130 A5 JP 2017530130A5 JP 2017516415 A JP2017516415 A JP 2017516415A JP 2017516415 A JP2017516415 A JP 2017516415A JP 2017530130 A5 JP2017530130 A5 JP 2017530130A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administration
- annexin
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 102000004121 Annexin A5 Human genes 0.000 claims 4
- 108090000672 Annexin A5 Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059669P | 2014-10-03 | 2014-10-03 | |
| US62/059,669 | 2014-10-03 | ||
| PCT/US2015/053828 WO2016054574A1 (en) | 2014-10-03 | 2015-10-02 | Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017530130A JP2017530130A (ja) | 2017-10-12 |
| JP2017530130A5 true JP2017530130A5 (OSRAM) | 2018-11-01 |
Family
ID=55631651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516415A Pending JP2017530130A (ja) | 2014-10-03 | 2015-10-02 | 腫瘍が誘発する自然免疫応答の免疫抑制を阻害する方法としてのアネキシンｖの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11253568B2 (OSRAM) |
| EP (1) | EP3200811A4 (OSRAM) |
| JP (1) | JP2017530130A (OSRAM) |
| KR (1) | KR20170063722A (OSRAM) |
| AU (1) | AU2015327887A1 (OSRAM) |
| CA (1) | CA2962255A1 (OSRAM) |
| WO (1) | WO2016054574A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10519504B2 (en) | 2009-05-11 | 2019-12-31 | Berg Llc | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| EP2694463B8 (en) | 2011-04-04 | 2019-10-09 | Berg LLC | Treating central nervous system tumors with coenzyme q10 |
| EA032775B1 (ru) | 2013-04-08 | 2019-07-31 | Берг Ллк | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 |
| WO2015035094A1 (en) | 2013-09-04 | 2015-03-12 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
| WO2016054574A1 (en) * | 2014-10-03 | 2016-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response |
| WO2017087576A1 (en) | 2015-11-16 | 2017-05-26 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| US20180021270A1 (en) * | 2016-07-21 | 2018-01-25 | Berg Llc | Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators |
| WO2019010181A1 (en) * | 2017-07-05 | 2019-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | USE OF ANNEXIN V TO REDUCE THE PROPAGATION OF INTRACELLULAR PATHOGENIC AGENTS |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| JP2023537210A (ja) * | 2020-07-09 | 2023-08-31 | 中国科学院上海薬物研究所 | Ｙｔｈｄｆ１を阻害するための組成物および方法 |
| WO2022212352A1 (en) * | 2021-03-29 | 2022-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Reversal of ctl exhaustion with annexin v |
| WO2023130112A1 (en) * | 2022-01-03 | 2023-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Blocking and reversing extracellular vesicle driven transcriptomic transformation with annexin v treatment |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7262167B2 (en) * | 1995-11-06 | 2007-08-28 | Exibona Ltd. | Drug, in particular for modulating the immunological response for the control of viruses, tumors, bacteria and parasites |
| US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
| US7635680B2 (en) * | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
| US6726895B2 (en) * | 2001-04-03 | 2004-04-27 | Board Of Trustees Of The Leland Stanford Junior University | Method of imaging cell death in vivo |
| DE10145254A1 (de) * | 2001-09-13 | 2003-04-10 | November Ag Molekulare Medizin | Verwendung eines Proteins zur Herstellung eines Medikaments zur Stimulierung einer inflammatorischen zellulären Immunantwort |
| DE10302422A1 (de) * | 2003-01-21 | 2004-07-29 | Responsif Gmbh | Medikament und Verwendung zur Tumortherapie |
| US8071545B2 (en) | 2005-03-15 | 2011-12-06 | Lewis S. Coleman, Md, Inc. | Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism |
| GB0911042D0 (en) | 2009-06-25 | 2009-08-12 | Istituto Superiore Di Sanito | Treatment of tumorigenic cells in solid tumours |
| WO2016054574A1 (en) * | 2014-10-03 | 2016-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response |
-
2015
- 2015-10-02 WO PCT/US2015/053828 patent/WO2016054574A1/en not_active Ceased
- 2015-10-02 KR KR1020177010186A patent/KR20170063722A/ko not_active Withdrawn
- 2015-10-02 US US15/515,033 patent/US11253568B2/en active Active
- 2015-10-02 CA CA2962255A patent/CA2962255A1/en not_active Abandoned
- 2015-10-02 JP JP2017516415A patent/JP2017530130A/ja active Pending
- 2015-10-02 EP EP15846422.2A patent/EP3200811A4/en active Pending
- 2015-10-02 AU AU2015327887A patent/AU2015327887A1/en not_active Abandoned
-
2022
- 2022-01-12 US US17/574,223 patent/US20220160829A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530130A5 (OSRAM) | ||
| Wu et al. | Peptide-based cancer therapy: opportunity and challenge | |
| Wallach et al. | Advances in the treatment of neuromyelitis optica spectrum disorder | |
| MX2015004565A (es) | Metodo y dispositivo para conmutacion de camaras. | |
| WO2017079746A3 (en) | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer | |
| IL278423B1 (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
| JP2012180381A5 (OSRAM) | ||
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| JP2013501816A5 (OSRAM) | ||
| JP2016515561A5 (OSRAM) | ||
| JP2015517488A5 (OSRAM) | ||
| IN2014MN00333A (OSRAM) | ||
| WO2014058979A8 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| JP2017503014A5 (OSRAM) | ||
| HRP20210552T1 (hr) | Liječenje multiplog mijeloma (mm) | |
| BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
| MX388073B (es) | Composición farmacéutica, preparación y usos de la misma. | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| Ignatova et al. | HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab? | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| JP2016515137A5 (OSRAM) | ||
| WO2017132445A8 (en) | Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor | |
| MX2017014776A (es) | Combinacion farmaceutica de everolimus con dactolisib. |